Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to
Hans Minderman, PhD
Advertisement
Articles by Hans Minderman, PhD
Advertisement
Latest Updated Articles
- Rational Design of Irinotecan Administration Based on Preclinical Models
Published: August 1st 1998 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
